Get the Stockscreener App
1.2099
0.83%
0.0099
Brainstorm Cell Therapeutics Inc stock is traded at $1.2099, with a volume of 67,649.
It is up +0.83% in the last 24 hours and down -2.43% over the past month.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
See More
Previous Close:
$1.20
Open:
$1.2
24h Volume:
67,649
Relative Volume:
0.05
Market Cap:
$11.86M
Revenue:
-
Net Income/Loss:
$-16.63M
P/E Ratio:
-2.8137
EPS:
-0.43
Net Cash Flow:
$-21.84M
1W Performance:
-2.43%
1M Performance:
-2.43%
6M Performance:
-39.20%
1Y Performance:
-80.04%
1-Day Range:
$1.19
$1.23
1-Week Range:
$1.17
$1.255
52-Week Range:
$0.7233
$6.30
Brainstorm Cell Therapeutics Inc Stock (BCLI) Company Profile
Name
Brainstorm Cell Therapeutics Inc
Sector
Industry
Phone
201-488-0460
Address
1325 AVENUE OF AMERICAS, NEW YORK, NY
Compare BCLI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCLI
Brainstorm Cell Therapeutics Inc
|
1.2051 | 12.89M | 0 | -16.63M | -21.84M | -0.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.17 | 119.76B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.34 | 59.14B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
319.34 | 41.40B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.21 | 32.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
278.89 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Brainstorm Cell Therapeutics Inc Stock (BCLI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-21 | Upgrade | Maxim Group | Hold → Buy |
| Nov-17-20 | Downgrade | Maxim Group | Buy → Hold |
| Dec-19-16 | Reiterated | Maxim Group | Buy |
| Dec-22-15 | Reiterated | Maxim Group | Buy |
Brainstorm Cell Therapeutics Inc Stock (BCLI) Latest News
FDA to review citizen petition on BrainStorm’s ALS therapy NurOwn By Investing.com - Investing.com South Africa
ALS Community Petitions FDA To Reconsider BrainStorm’s NurOwn, Pointing to Recent Survival Data - BioSpace
BTCS, BrainStorm Cell, Moderna - TradingView
BrainStorm Cell Therapeutics: A Rare Disease Breakthrough on the Brink of Regulatory Approval - AInvest
NurOwn's Regulatory Crossroads: Why BrainStorm Cell Therapeutics (BCLI) Could Be Poised for a Turnaround - AInvest
FDA to review citizen petition on BrainStorm’s ALS therapy NurOwn - Investing.com
FDA Review of Citizen Petition Offers a Fresh Look at NurOwn®'s Evidence of Treatment Effectiveness - Nasdaq
BCLI: Citizen's Petition Filed Requesting the FDA Approve NurOwn - Smartkarma
ALS Community Files Citizens’ Petition asking FDA to Approve NurOwn Stem Cell Therapy - Asbury Park Press
SHAREHOLDER ALERT: Potential Recovery for Brainstorm Cell Therapeutics Inc. (BCLI) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Press Release Service: Gene and Cell Therapies Targeting CNS Disorders Market Research 2025-2035 | Novartis, BrainStorm Cell Therapeutics, Neuroplast, Rapa Therapeutics, and Longeveron Driving InnovationsResearchAndMarkets.com - CRISPR Medicine News
Brainstorm Cell Therapeutics Approves Stock Plan Amendments - TipRanks
9 of 10 NurOwn-treated ALS patients surpass five-year survival - ALS News Today
Autologous Cell Therapy Market Size, Global Trends And Forecast to 2033 - Straits Research
Brainstorm Cell's NurOwn Study Data Shows 90% Survival Rate In ALS Patients, Stock Up In Pre-Market - Nasdaq
Encouraging Survival Data Revealed for BrainStorm's NurOwn in ALS Study (BCLI) | BCLI Stock News - GuruFocus
BrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn® - PR Newswire
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Rating Increased to Sell at Wall Street Zen - Defense World
Corestemchemon preps US BLA filing for stem cell ALS therapy - BioWorld MedTech
Brainstorm taps Minaris to produce NurOwn for Phase 3b trial - ALS News Today
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Brainstorm Cell Therapeutics Inc.(BCLI) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Neuromuscular Disease Therapeutics Market Growth Driven - openPR.com
5 Best Stem Cell Companies to Invest In (June 2025) - Securities.io
What is Zacks Small Cap’s Estimate for BCLI FY2025 Earnings? - Defense World
Q2 Earnings Estimate for BCLI Issued By Zacks Small Cap - Defense World
BCLI: Receives Regulatory Clearance to Initiate Phase 3b ALS Trial… - MSN
BrainStorm Cell Therapeutics and Minaris partner on manufacturing NurOwn for trial - Yahoo Finance
BrainStorm partners with Minaris for ALS therapy trial By Investing.com - Investing.com South Africa
BrainStorm partners with Minaris for ALS therapy trial - Investing.com Australia
BrainStorm Cell Therapeutics (BCLI) Partners with Minaris for Nu - GuruFocus
BrainStorm Cell Therapeutics (BCLI) Partners with Minaris for NurOwn Manufacturing | BCLI Stock News - GuruFocus
BrainStorm Accelerates NurOwn ALS Treatment Development Through Major Manufacturing Deal with Minaris - Stock Titan
INVESTOR ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 2, 2024 in Brainstorm Cell Lawsuit – BCLI - ACCESS Newswire
FDA clears Phase 3b trial of NurOwn for ALS - ALS News Today
Gene And Cell Therapies Targeting Cns Disorders Market in 2025 - openPR.com
Pre-market Movers: VIGL, CVM, KDLY, VTAK... - RTTNews
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Earns Hold Rating from Analysts at StockNews.com - Defense World
Brainstorm Cell Therapeutics outlines imminent Phase 3b ALS trial launch following FDA clearance and expanded manufacturing plans - MSN
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q1 2025 Earnings Call Transcript - Insider Monkey
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
What Did We Note About Insider Trading At Brainstorm Cell Therapeutics, Inc (NASDAQ: BCLI)? - Stocksregister
FDA grants clearance to BrainStorm’s Phase IIIb trial of ALS treatment - Yahoo Finance
Retail Bulls Cheer FDA Clearance For BrainStorm’s ALS Therapy, But Shares Dip After Hours By Stocktwits - Investing.com India
Brainstorm Cell Therapeutics Reports Q1 2025 Financials - TipRanks
BrainStorm advances ALS treatment with FDA trial nod By Investing.com - Investing.com South Africa
BrainStorm advances ALS treatment with FDA trial nod - Investing.com Australia
Sector Update: Health Care Stocks Advance Monday Afternoon - marketscreener.com
Top Midday Gainers - marketscreener.com
BrainStorm (BCLI) Options Delisting Announced | BCLI Stock News - GuruFocus
Brainstorm Cell Therapeutics (BCLI) Advances Phase 3b ALS Trial - GuruFocus
Earnings call transcript: BrainStorm Cell Therapeutics Q1 2025 sees stock surge after trial updates - Investing.com Nigeria
Brainstorm Cell Therapeutics Inc Stock (BCLI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Brainstorm Cell Therapeutics Inc Stock (BCLI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lebovits Chaim | President & CEO |
Sep 30 '24 |
Buy |
0.23 |
22,000 |
5,016 |
1,186,865 |
| Dagher Ibrahim B. | Chief Medical Officer |
Jul 19 '24 |
Sale |
0.35 |
63,000 |
22,069 |
0 |
2.91%
1.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):